Aptamers as theranostic agents: Modifications, serum stability and functionalisation

Sensors (Switzerland)

Volumn 13, Issue 10, 2013, Pages 13624-13637

  Shigdar, Sarah ^a   Macdonald, Joanna ^a   O'Connor, Michael ^a   Wang, Tao ^a   Xiang, Dongxi ^a   Shamaileh, Hadi Al ^a   Qiao, Liang ^b   Wei, Ming ^c   Zhou, Shu Feng ^d   Zhu, Yimin ^e   Kong, Lingxue ^a   Bhattacharya, Santanu ^f   Li, ChunGuang ^g   Duan, Wei ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e SUZHOU INSTITUTE OF NANO TECH AND NANO BIONICS   (China)

^f INDIAN INSTITUTE OF SCIENCE   (India)

^g WESTERN SYDNEY UNIVERSITY   (Australia)

Author keywords

Aptamer; Cancer; Diagnostics; Locked nucleic acid; SELEX; Unlocked nucleic acid

Indexed keywords

NUCLEIC ACIDS; PLASMA DIAGNOSTICS;

APTAMERS; CANCER; DIAGNOSTIC AGENTS; LOCKED NUCLEIC ACID; SELECTION PROCEDURES; SELEX; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENTS; THERANOSTIC AGENTS;

BODY FLUIDS;

EID: 84885364568     PISSN: 14248220     EISSN: None     Source Type: Journal    
DOI: 10.3390/s131013624     Document Type: Review

References (75)

1. Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346, 818-822.
2. Robertson, D.L.; Joyce, G.F. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 1990, 344, 467-468.
3. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249, 505-510.
4. Paterson, B.M.; Roberts, B.E.; Kuff, E.L. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc. Natl. Acad. Sci. USA. 1977, 74, 4370-4374.
5. Stephenson, M.L.; Zamecnik, P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA. 1978, 75, 285-288.
6. Shigdar, S.; Lin, J.; Yu, Y.; Pastuovic, M.; Wei, M.; Duan, W. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 2011, 102, 991-998.
7. Shigdar, S.; Qiao, L.; Zhou, S.; Xiang, D.; Wang, T.; Li, Y.; Lim, L.Y.; Kong, L.; Li, L.; Duan, W. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett. 2013, 330, 84-95.
8. Shangguan, D.; Cao, Z.H.; Meng, L.; Mallikaratchy, P.; Sefah, K.; Wang, H.; Li, Y.; Tan, W.H. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. 2008, 7, 2133-2139.
9. Sefah, K.; Shangguan, D.; Xiong, X.; O'Donoghue, M.B.; Tan, W. Development of DNA aptamers using Cell-SELEX. Nat. Protoc. 2010, 5, 1169-1185.
10. Adler, A.; Forster, N.; Homann, M.; Goringer, H.U. Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer. Comb. Chem. High Throughput Screen 2008, 11, 16-23.
11. Mi, J.; Liu, Y.; Rabbani, Z.N.; Yang, Z.; Urban, J.H.; Sullenger, B.A.; Clary, B.M. In vivo selection of tumor-targeting RNA motifs. Nat. Chem. Biol. 2010, 6, 22-24.
12. Cheng, C.; Chen, Y.H.; Lennox, K.A.; Behlke, M.A.; Davidson, B.L. In vivo SELEX for Identification of Brain-penetrating Aptamers. Mol. Ther. Nucleic Acids 2013, 2, e67.
13. White, R.R.; Sullenger, B.A.; Rusconi, C.P. Developing aptamers into therapeutics. J. Clin. Invest. 2000, 106, 929-934.
14. Djordjevic, M. SELEX experiments: New prospects, applications and data analysis in inferring regulatory pathways. Biomol. Eng. 2007, 24, 179-189.
15. Kato, Y.; Minakawa, N.; Komatsu, Y.; Kamiya, H.; Ogawa, N.; Harashima, H.; Matsuda, A. New NTP analogs: The synthesis of 4'-thioUTP and 4'-thioCTP and their utility for SELEX. Nucleic Acids Res. 2005, 33, 2942-2951.
16. Hofacker, I.L. Vienna RNA secondary structure server. Nucleic Acids Res. 2003, 31, 3429-3431.
17. Sato, K.; Hamada, M.; Asai, K.; Mituyama, T. CENTROIDFOLD: A web server for RNA secondary structure prediction. Nucleic Acids Res. 2009, 37, W277-W280.
18. Shigdar, S.; Ward, A.C.; De, A.; Yang, C.J.; Wei, M.; Duan, W. Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies. Br. J. Haematol. 2011, 155, 3-13.
19. Wilson, C.; Keefe, A.D. Building oligonucleotide therapeutics using non-natural chemistries. Curr. Opin. Chem. Biol. 2006, 10, 607-614.
20. Samani, T.D.; Jolles, B.; Laigle, A. Best minimally modified antisense oligonucleotides according to cell nuclease activity. Antisense Nucleic Acid Drug Dev. 2001, 11, 129-136.
21. Peyman, A.; Uhlmann, E. Minimally modified oligonucleotides-combination of end-capping and pyrimidine-protection. Biol. Chem. Hoppe Seyler 1996, 377, 67-70.
22. Dean, N.M.; Bennett, C.F. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003, 22, 9087-9096.
23. Lee, J.F.; Stovall, G.M.; Ellington, A.D. Aptamer therapeutics advance. Curr. Opin. Chem. Biol. 2006, 10, 282-289.
24. Pendergrast, P.S.; Marsh, H.N.; Grate, D.; Healy, J.M.; Stanton, M. Nucleic acid aptamers for target validation and therapeutic applications. J. Biomol. Tech. 2005, 16, 224-234.
25. Hou, Y.M.; Zhang, X.; Holland, J.A.; Davis, D.R. An important 2'-OH group for an RNA-protein interaction. Nucleic Acids Res. 2001, 29, 976-985.
26. Bunka, D.H.; Stockley, P.G. Aptamers come of age-At last. Nat. Rev. Microbiol. 2006, 4, 588-596.
27. Kasahara, Y.; Kuwahara, M. Artificial specific binders directly recovered from chemically modified nucleic Acid libraries. J. Nucleic Acids 2012, 2012, 156482.
28. Saenger, W. Structure and function of nucleosides and nucleotides. Angew Chem. Int. Ed. Engl. 1973, 12, 591-601.
29. Kuwahara, M.; Sugimoto, N. Molecular evolution of functional nucleic acids with chemical modifications. Molecules 2010, 15, 5423-5444.
30. Keefe, A.D.; Cload, S.T. SELEX with modified nucleotides. Curr. Opin. Chem. Biol. 2008, 12, 448-456.
31. Schmidt, K.S.; Borkowski, S.; Kurreck, J.; Stephens, A.W.; Bald, R.; Hecht, M.; Friebe, M.; Dinkelborg, L.; Erdmann, V.A. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res. 2004, 32, 5757-5765.
32. Shangguan, D.; Tang, Z.; Mallikaratchy, P.; Xiao, Z.; Tan, W. Optimization and modifications of aptamers selected from live cancer cell lines. Chembiochem 2007, 8, 603-606.
33. Cerchia, L.; Duconge, F.; Pestourie, C.; Boulay, J.; Aissouni, Y.; Gombert, K.; Tavitian, B.; de Franciscis, V.; Libri, D. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLos Biol. 2005, 3, 697-704.
34. Damha, M.J.; Meng, B.; Wang, D.; Yannopoulos, C.G.; Just, G. Structural basis for the RNA binding selectivity of oligonucleotide analogues containing alkylsulfide internucleoside linkages and 2'-substituted 3'-deoxyribonucleosides. Nucleic Acids Res. 1995, 23, 3967-3973.
35. Lee, J.H.; Canny, M.D.; de Erkenez, A.; Krilleke, D.; Ng, Y.S.; Shima, D.T.; Pardi, A.; Jucker, F. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc. Natl. Acad. Sci. USA. 2005, 102, 18902-18907.
36. Kaur, G.; Roy, I. Therapeutic applications of aptamers. Expert Opin. Investig. Drugs 2008, 17, 43-60.
37. Koshkin, A.A.; Singh, S.K.; Nielsen, P.; Rajwanshi, V.K.; Kumar, R.; Meldgaard, M.; Olsen, C.E.; Wengel, J. LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 1998, 54, 3607-3630.
38. Obika, S.; Nanbu, D.; Hari, Y.; Andoh, J.I.; Morio, K.I.; Doi, T.; Imanishi, T. Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2'-O,4'-C-methyleneribonucleosides. Tetrahedron Lett. 1998, 39, 5401-5404.
39. Petersen, M.; Wengel, J. LNA: A versatile tool for therapeutics and genomics. Trends Biotechnol. 2003, 21, 74-81.
40. Sorensen, M.D.; Kvaerno, L.; Bryld, T.; Hakansson, A.E.; Verbeure, B.; Gaubert, G.; Herdewijn, P.; Wengel, J. alpha-L-ribo-configured locked nucleic acid (alpha-L-LNA): Synthesis and properties. J. Am. Chem. Soc. 2002, 124, 2164-2176.
41. Doessing, H.; Vester, B. Locked and unlocked nucleosides in functional nucleic acids. Molecules 2011, 16, 4511-4526.
42. Mallikaratchy, P.; Tang, Z.W.; Kwame, S.; Meng, L.; Shangguan, D.H.; Tan, W.H. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol. Cell. Proteomics 2007, 6, 2230-2238.
43. Mallikaratchy, P.R.; Ruggiero, A.; Gardner, J.R.; Kuryavyi, V.; Maguire, W.F.; Heaney, M.L.; McDevitt, M.R.; Patel, D.J.; Scheinberg, D.A. A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res. 2011, 39, 2458-2469.
44. Pasternak, A.; Wengel, J. Unlocked nucleic acid-An RNA modification with broad potential. Org. Biomol. Chem. 2011, 9, 3591-3597.
45. Campbell, M.A.; Wengel, J. Locked vs. unlocked nucleic acids (LNA vs. UNA): Contrasting structures work towards common therapeutic goals. Chem. Soc. Rev. 2011, 40, 5680-5689.
46. Kusser, W. Chemically modified nucleic acid aptamers for in vitro selections: Evolving evolution. J. Biotechnol. 2000, 74, 27-38.
47. Padilla, R.; Sousa, R. Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2'-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res. 1999, 27, 1561-1563.
48. Padilla, R.; Sousa, R. A Y639F/H784A T7 RNA polymerase double mutant displays superior properties for synthesizing RNAs with non-canonical NTPs. Nucleic Acids Res. 2002, 30, e138.
49. Chelliserrykattil, J.; Ellington, A.D. Evolution of a T7 RNA polymerase variant that transcribes 2'-O-methyl RNA. Nat. Biotechnol. 2004, 22, 1155-1160.
50. Imaizumi, Y.; Kasahara, Y.; Fujita, H.; Kitadume, S.; Ozaki, H.; Endoh, T.; Kuwahara, M.; Sugimoto, N. Efficacy of base-modification on target binding of small molecule DNA aptamers. J. Am. Chem. Soc. 2013, 135, 9412-9419.
51. Shoji, A.; Kuwahara, M.; Ozaki, H.; Sawai, H. Modified DNA aptamer that binds the (R)-isomer of a thalidomide derivative with high enantioselectivity. J. Am. Chem. Soc. 2007, 129, 1456-1464.
52. Vaught, J.D.; Bock, C.; Carter, J.; Fitzwater, T.; Otis, M.; Schneider, D.; Rolando, J.; Waugh, S.; Wilcox, S.K.; Eaton, B.E. Expanding the chemistry of DNA for in vitro selection. J. Am. Chem. Soc. 2010, 132, 4141-4151.
53. Gold, L.; Ayers, D.; Bertino, J.; Bock, C.; Bock, A.; Brody, E.N.; Carter, J.; Dalby, A.B.; Eaton, B.E.; Fitzwater, T.; et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010, 5, e15004.
54. Davies, D.R.; Gelinas, A.D.; Zhang, C.; Rohloff, J.C.; Carter, J.D.; O'Connell, D.; Waugh, S.M.; Wolk, S.K.; Mayfield, W.S.; Burgin, A.B.; et al. Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc. Natl. Acad. Sci. USA. 2012, 109, 19971-19976.
55. Veedu, R.N.; Vester, B.; Wengel, J. Polymerase chain reaction and transcription using locked nucleic acid nucleotide triphosphates. J. Am. Chem. Soc. 2008, 130, 8124-8125.
56. Crouzier, L.; Dubois, C.; Edwards, S.L.; Lauridsen, L.H.; Wengel, J.; Veedu, R.N. Efficient reverse transcription using locked nucleic acid nucleotides towards the evolution of nuclease resistant RNA aptamers. PLoS One 2012, 7, e35990.
57. Doessing, H.; Hansen, L.H.; Veedu, R.N.; Wengel, J.; Vester, B. Amplification and re-generation of LNA-modified libraries. Molecules 2012, 17, 13087-13097.
58. Kasahara, Y.; Irisawa, Y.; Ozaki, H.; Obika, S.; Kuwahara, M. 2',4'-BNA/LNA aptamers: CE-SELEX using a DNA-based library of full-length 2'-O,4'-C-methylene-bridged/linked bicyclic ribonucleotides. Bioorg. Med. Chem. Lett. 2013, 23, 1288-1292.
59. Kuwahara, M.; Obika, S. In vitro selection of BNA (LNA) aptamers. Artif DNA PNA XNA 2013, 4, 39-48.
60. Kasahara, Y.; Irisawa, Y.; Fujita, H.; Yahara, A.; Ozaki, H.; Obika, S.; Kuwahara, M. Capillary electrophoresis-systematic evolution of ligands by exponential enrichment selection of base-and sugar-modified DNA aptamers: Target binding dominated by 2'-O,4'-C-methylene-bridged/locked nucleic acid primer. Anal. Chem. 2013, 85, 4961-4967.
61. Pinheiro, V.B.; Taylor, A.I.; Cozens, C.; Abramov, M.; Renders, M.; Zhang, S.; Chaput, J.C.; Wengel, J.; Peak-Chew, S.Y.; et al. Synthetic genetic polymers capable of heredity and evolution. Science 2012, 336, 341-344.
62. Song, K.M.; Lee, S.; Ban, C. Aptamers and their biological applications. Sensors 2012, 12, 612-631.
63. Shi, H.; Tang, Z.; Kim, Y.; Nie, H.; Huang, Y.F.; He, X.; Deng, K.; Wang, K.; Tan, W. In vivo fluorescence imaging of tumors using molecular aptamers generated by cell-SELEX. Chem. Asian J. 2010, 5, 2209-2213.
64. Gao, X.; Cui, Y.; Levenson, R.M.; Chung, L.W.; Nie, S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 2004, 22, 969-976.
65. Michalet, X.; Pinaud, F.F.; Bentolila, L.A.; Tsay, J.M.; Doose, S.; Li, J.J.; Sundaresan, G.; Wu, A.M.; Gambhir, S.S.; Weiss, S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307, 538-544.
66. Texier, I.; Josser, V. In vivo imaging of quantum dots. Methods Mol. Biol. 2009, 544, 393-406.
67. Bentolila, L.A.; Ebenstein, Y.; Weiss, S. Quantum dots for in vivo small-animal imaging. J. Nucl. Med. 2009, 50, 493-496.
68. Kang, W.J.; Chae, J.R.; Cho, Y.L.; Lee, J.D.; Kim, S. Multiplex imaging of single tumor cells using quantum-dot-conjugated aptamers. Small 2009, 5, 2519-2522.
69. Zhang, M.Z.; Yu, R.N.; Chen, J.; Ma, Z.Y.; Zhao, Y.D. Targeted quantum dots fluorescence probes functionalized with aptamer and peptide for transferrin receptor on tumor cells. Nanotechnology 2012, 23, 485104.
70. Levy, M.; Cater, S.F.; Ellington, A.D. Quantum-dot aptamer beacons for the detection of proteins. ChemBioChem 2005, 6, 2163-2166.
71. Mohan, P.; Rapoport, N. Doxorubicin as a molecular nanotheranostic agent: Effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol. Pharm. 2010, 7, 1959-1973.
72. Bagalkot, V.; Farokhzad, O.C.; Langer, R.; Jon, S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 2006, 45, 8149-8152.
73. Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P.W.; Langer, R.; Farokhzad, O.C. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano. Lett. 2007, 7, 3065-3070.
74. Wang, A.Z.; Bagalkot, V.; Vasilliou, C.C.; Gu, F.; Alexis, F.; Zhang, L.; Shaikh, M.; Yuet, K.; Cima, M.J.; Langer, R.; et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008, 3, 1311-1315.
75. McNamara, J.O., II; Andrechek, E.R.; Wang, Y.; Viles, K.D.; Rempel, R.E.; Gilboa, E.; Sullenger, B.A.; Giangrande, P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24, 1005-1015.